OLUMIANT

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug OLUMIANT contains one active pharmaceutical ingredient (API):

1 Baricitinib UNII ISP4442I3Y - BARICITINIB

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and >400 nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Read about Baricitinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OLUMIANT Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AF02		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11437Y, 11442F, 11443G, 11447L
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 507619020021501, 507619020021601, 507619020021701, 507619020021801
Country: CA	Health Products and Food Branch	Identifier(s): 02480018
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 4543-MEE-0119, 4806-MEE-0919
Country: EE	Ravimiamet	Identifier(s): 1739189, 1739190, 1739202, 1739213, 1739224, 1739235, 1739246, 1739257, 1739268, 1739279, 1739280, 1739291
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1161170002, 1161170010
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 407393, 579910
Country: FR	Base de données publique des médicaments	Identifier(s): 61751780, 63788717
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 343458, 346212
Country: HK	Department of Health Drug Office	Identifier(s): 65663, 65664
Country: IE	Health Products Regulatory Authority	Identifier(s): 88875, 88876
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8307, 8308
Country: IT	Agenzia del Farmaco	Identifier(s): 045260015, 045260027, 045260039, 045260041, 045260054, 045260066, 045260078, 045260080, 045260092, 045260104, 045260116, 045260128, 045260130, 045260142, 045260155, 045260167, 045260179, 045260181, 045260193
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999043F1020, 3999043F2026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082320, 1082321, 1082322, 1082323, 1082324, 1082325, 1082326, 1082327, 1082328, 1082329, 1082330, 1082331, 1082332, 1082333, 1082334, 1082335
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 140848, 140856
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100386120, 100386137
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W63493001, W65630001
Country: SG	Health Sciences Authority	Identifier(s): 15504P, 15505P
Country: US	FDA, National Drug Code	Identifier(s): 0002-4182, 0002-4732
Country: ZA	Health Products Regulatory Authority	Identifier(s): 52/3.1/0229, 52/3.1/0230